The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 354:1747-1751 April 20, 2006 Number 16
NextNext

Rotavirus Vaccines

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Glass, R. I.
-Related Article
by Ruiz-Palacios, G. M.
-Related Article
by Vesikari, T.
-PubMed Citation
To the Editor: The rotavirus vaccines in the clinical trials reported on by Ruiz-Palacios and colleagues and Vesikari and colleagues (Jan. 5 issue)1,2 may reduce mortality from rotavirus less efficaciously in Third World regions where rotavirus expresses the VP4, VP6, and VP7 serotypes not included in the vaccines. Furthermore, because of the "original antigenic sins" of B cells3 and T cells,4 infants who are vaccinated before contracting natural rotavirus infections may become hyporesponsive to indigenous rotavirus because of the development of recall immunity, which is anamnestically more reactive with vaccine than with local serotypes. Paradoxically, if this recurrent vaccine-specific response . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.